B-intervention	0	8	Explicit
I-intervention	9	19	prognostic
I-intervention	20	30	disclosure
O	31	33	to
B-ethinicity	34	39	Asian
O	40	45	women
O	46	50	with
O	51	57	breast
O	58	64	cancer
O	64	65	:
O	66	67	A
O	68	78	randomized
O	78	79	,
O	80	88	scripted
O	89	94	video
O	94	95	-
O	95	103	vignette
O	104	109	study
O	110	111	(
O	111	112	J
O	112	113	-
O	113	124	SUPPORT1601
O	124	125	)
O	125	126	.

O	127	140	Nondisclosure
O	141	143	of
O	144	145	a
O	146	150	poor
O	151	160	prognosis
O	161	163	to
O	164	172	patients
O	173	177	with
O	178	186	advanced
O	187	193	cancer
O	194	201	remains
O	202	203	a
O	204	211	typical
O	212	220	practice
O	221	223	in
O	224	228	Asia
O	228	229	.

O	230	238	Although
O	239	242	the
O	243	253	importance
O	254	256	of
O	257	267	prognostic
O	268	281	communication
O	282	285	has
O	286	298	increasingly
O	299	303	been
O	304	314	recognized
O	315	324	worldwide
O	324	325	,
O	326	332	little
O	333	335	is
O	336	341	known
O	342	347	about
O	348	355	whether
O	356	364	explicit
O	365	375	prognostic
O	376	386	disclosure
O	387	397	positively
O	398	405	affects
O	406	411	Asian
O	412	420	patients
O	421	425	with
O	426	434	advanced
O	435	441	cancer
O	441	442	.

O	443	446	The
O	447	456	objective
O	457	459	of
O	460	464	this
O	465	470	study
O	471	474	was
O	475	477	to
O	478	485	examine
O	486	489	the
O	490	497	effects
O	498	500	of
O	501	509	explicit
O	510	520	prognostic
O	521	534	communication
O	535	537	on
O	538	546	patients
O	547	551	with
O	552	558	cancer
O	559	569	recurrence
O	569	570	.

O	571	573	In
O	574	578	this
O	579	589	randomized
O	589	590	,
O	591	596	video
O	596	597	-
O	597	605	vignette
O	606	611	study
O	611	612	,
B-ethinicity	613	621	Japanese
B-eligibility	622	627	women
I-eligibility	628	632	with
I-eligibility	633	639	breast
I-eligibility	640	646	cancer
I-eligibility	647	650	who
I-eligibility	651	654	had
I-eligibility	655	664	undergone
I-eligibility	665	673	curative
I-eligibility	674	681	surgery
O	682	688	viewed
O	689	695	videos
O	696	698	of
O	699	709	prognostic
O	710	723	communication
O	724	731	between
O	732	733	a
O	734	741	patient
O	742	746	with
O	747	756	recurrent
O	756	757	,
O	758	767	incurable
O	768	774	breast
O	775	781	cancer
O	782	785	and
O	786	789	her
O	790	800	oncologist
O	800	801	.

O	802	805	The
O	806	812	videos
O	813	821	differed
O	822	826	only
O	827	829	in
O	830	833	the
O	834	842	presence
O	843	845	or
O	846	853	absence
O	854	856	of
O	857	865	explicit
O	866	876	prognostic
O	877	887	disclosure
O	887	888	.

O	889	892	The
O	893	900	primary
O	901	908	outcome
O	909	912	was
B-outcome-Measure	913	925	participants
I-outcome-Measure	925	926	'
I-outcome-Measure	927	938	uncertainty
O	939	940	(
O	940	945	rated
O	946	950	from
O	951	952	0
O	953	955	to
O	956	958	10
O	958	959	)
O	959	960	,
O	961	964	and
O	965	968	the
O	969	978	secondary
O	979	987	outcomes
O	988	996	included
B-outcome-Measure	997	1004	anxiety
O	1005	1006	(
O	1006	1014	measured
O	1015	1017	on
O	1018	1021	the
O	1022	1027	State
O	1027	1028	-
O	1028	1033	Trait
O	1034	1041	Anxiety
O	1042	1051	Inventory
O	1051	1052	-
O	1052	1057	State
O	1057	1058	:
O	1059	1064	range
O	1064	1065	,
O	1066	1068	20
O	1068	1069	-
O	1069	1071	80
O	1071	1072	)
O	1072	1073	,
B-outcome-Measure	1074	1086	satisfaction
O	1087	1088	(
O	1088	1095	Patient
O	1096	1108	Satisfaction
O	1109	1122	Questionnaire
O	1122	1123	;
O	1124	1129	range
O	1130	1131	0
O	1131	1132	-
O	1132	1134	10
O	1134	1135	)
O	1135	1136	,
B-outcome-Measure	1137	1141	self
I-outcome-Measure	1141	1142	-
I-outcome-Measure	1142	1150	efficacy
O	1151	1152	(
O	1152	1157	range
O	1157	1158	,
O	1159	1160	0
O	1160	1161	-
O	1161	1163	10
O	1163	1164	)
O	1164	1165	,
O	1166	1169	and
B-outcome-Measure	1170	1181	willingness
I-outcome-Measure	1182	1184	to
I-outcome-Measure	1185	1192	discuss
I-outcome-Measure	1193	1200	advance
I-outcome-Measure	1201	1205	care
I-outcome-Measure	1206	1214	planning
O	1215	1216	(
O	1216	1221	range
O	1221	1222	,
O	1223	1224	1
O	1224	1225	-
O	1225	1226	4
O	1226	1227	)
O	1227	1228	.

O	1229	1231	In
O	1232	1237	total
O	1237	1238	,
B-total-participants	1239	1242	105
O	1243	1248	women
O	1249	1261	participated
O	1262	1263	(
O	1263	1267	mean
O	1268	1269	±
O	1270	1272	SD
O	1273	1276	age
O	1276	1277	,
B-age	1278	1280	53
I-age	1280	1281	.
I-age	1281	1282	8
I-age	1283	1284	±
I-age	1285	1286	8
I-age	1286	1287	.
I-age	1287	1288	2
I-age	1289	1294	years
O	1294	1295	)
O	1295	1296	.

O	1297	1302	After
O	1303	1310	viewing
O	1311	1314	the
O	1315	1320	video
O	1321	1325	with
O	1326	1330	more
O	1331	1337	versus
O	1338	1342	less
O	1343	1351	explicit
O	1352	1362	disclosure
O	1362	1363	,
O	1364	1376	participants
O	1377	1383	showed
O	1384	1397	significantly
O	1398	1403	lower
B-outcome	1404	1415	uncertainty
O	1416	1417	(
O	1417	1421	mean
O	1422	1423	±
O	1424	1426	SE
O	1427	1433	scores
O	1433	1434	,
B-iv-cont-mean	1435	1436	5
I-iv-cont-mean	1436	1437	.
I-iv-cont-mean	1437	1438	3
O	1439	1440	±
B-iv-cont-sd	1440	1441	0
I-iv-cont-sd	1441	1442	.
I-iv-cont-sd	1442	1443	2
O	1444	1446	vs
B-cv-cont-mean	1447	1448	5
I-cv-cont-mean	1448	1449	.
I-cv-cont-mean	1449	1450	7
O	1451	1452	±
B-cv-cont-sd	1453	1454	0
I-cv-cont-sd	1454	1455	.
I-cv-cont-sd	1455	1456	2
O	1456	1457	,
O	1458	1470	respectively
O	1470	1471	;
O	1472	1473	P
O	1474	1475	=
O	1476	1477	.
O	1477	1480	032
O	1480	1481	)
O	1482	1485	and
O	1486	1492	higher
B-outcome	1493	1505	satisfaction
O	1506	1507	(
B-iv-cont-mean	1507	1508	5
I-iv-cont-mean	1508	1509	.
I-iv-cont-mean	1509	1510	6
O	1511	1512	±
B-iv-cont-sd	1513	1514	0
I-iv-cont-sd	1514	1515	.
I-iv-cont-sd	1515	1516	2
O	1517	1519	vs
B-cv-cont-mean	1520	1521	5
I-cv-cont-mean	1521	1522	.
I-cv-cont-mean	1522	1523	2
O	1524	1525	±
B-cv-cont-sd	1526	1527	0
I-cv-cont-sd	1527	1528	.
I-cv-cont-sd	1528	1529	2
O	1529	1530	,
O	1531	1543	respectively
O	1543	1544	;
O	1545	1546	P
O	1547	1548	=
O	1549	1550	.
O	1550	1553	010
O	1553	1554	)
O	1555	1562	without
O	1563	1573	increasing
B-outcome	1574	1581	anxiety
O	1582	1583	(
O	1583	1590	changes
O	1591	1593	in
O	1594	1600	scores
O	1601	1603	on
O	1604	1607	the
O	1608	1613	State
O	1613	1614	-
O	1614	1619	Trait
O	1620	1627	Anxiety
O	1628	1637	Inventory
O	1637	1638	-
O	1638	1643	State
O	1643	1644	:
B-iv-cont-mean	1645	1646	0
I-iv-cont-mean	1646	1647	.
I-iv-cont-mean	1647	1649	06
O	1650	1651	±
B-iv-cont-sd	1652	1653	0
I-iv-cont-sd	1653	1654	.
I-iv-cont-sd	1654	1655	5
O	1656	1658	vs
B-cv-cont-mean	1659	1660	0
I-cv-cont-mean	1660	1661	.
I-cv-cont-mean	1661	1662	6
O	1663	1664	±
B-cv-cont-sd	1665	1666	0
I-cv-cont-sd	1666	1667	.
I-cv-cont-sd	1667	1668	5
O	1668	1669	,
O	1670	1682	respectively
O	1682	1683	;
O	1684	1685	P
O	1686	1687	=
O	1688	1689	.
O	1689	1692	198
O	1692	1693	)
O	1693	1694	.

O	1695	1697	No
O	1698	1709	significant
O	1710	1721	differences
O	1722	1726	were
O	1727	1735	observed
O	1736	1738	in
B-outcome	1739	1743	self
I-outcome	1743	1744	-
I-outcome	1744	1752	efficacy
O	1753	1754	(
B-iv-cont-mean	1754	1755	5
I-iv-cont-mean	1755	1756	.
I-iv-cont-mean	1756	1757	2
O	1758	1759	±
B-iv-cont-sd	1760	1761	0
I-iv-cont-sd	1761	1762	.
I-iv-cont-sd	1762	1763	2
O	1764	1766	vs
B-cv-cont-mean	1767	1768	5
I-cv-cont-mean	1768	1769	.
I-cv-cont-mean	1769	1770	0
O	1771	1772	±
B-cv-cont-sd	1773	1774	0
I-cv-cont-sd	1774	1775	.
I-cv-cont-sd	1775	1776	2
O	1776	1777	,
O	1778	1790	respectively
O	1790	1791	;
O	1792	1793	P
O	1794	1795	=
O	1796	1797	.
O	1797	1800	277
O	1800	1801	)
O	1802	1804	or
B-outcome	1805	1816	willingness
I-outcome	1817	1819	to
I-outcome	1820	1827	discuss
I-outcome	1828	1835	advance
I-outcome	1836	1840	care
I-outcome	1841	1849	planning
O	1850	1851	(
B-iv-cont-mean	1851	1852	2
I-iv-cont-mean	1852	1853	.
I-iv-cont-mean	1853	1854	7
O	1855	1856	±
B-iv-cont-sd	1857	1858	0
I-iv-cont-sd	1858	1859	.
I-iv-cont-sd	1859	1860	1
O	1861	1863	vs
B-cv-cont-mean	1864	1865	2
I-cv-cont-mean	1865	1866	.
I-cv-cont-mean	1866	1867	7
O	1868	1869	±
B-cv-cont-sd	1870	1871	0
I-cv-cont-sd	1871	1872	.
I-cv-cont-sd	1872	1873	1
O	1873	1874	,
O	1875	1887	respectively
O	1887	1888	;
O	1889	1890	P
O	1891	1892	=
O	1893	1894	.
O	1894	1897	240
O	1897	1898	)
O	1898	1899	.

O	1900	1908	Explicit
O	1909	1919	prognostic
O	1920	1930	disclosure
O	1931	1939	prompted
O	1940	1946	better
O	1947	1955	outcomes
O	1956	1960	than
B-control	1961	1974	nondisclosure
O	1975	1977	in
O	1978	1986	Japanese
O	1987	1992	women
O	1993	1997	with
O	1998	2004	breast
O	2005	2011	cancer
O	2011	2012	.

O	2013	2017	When
O	2018	2023	asked
O	2024	2029	about
O	2030	2033	the
O	2034	2043	prognosis
O	2044	2046	by
O	2047	2052	Asian
O	2053	2061	patients
O	2062	2066	with
O	2067	2073	cancer
O	2073	2074	,
O	2075	2085	clinicians
O	2086	2089	may
O	2090	2092	be
O	2093	2103	encouraged
O	2104	2106	to
O	2107	2114	respect
O	2115	2120	their
O	2121	2127	wishes
O	2128	2131	and
O	2132	2142	explicitly
O	2143	2150	discuss
O	2151	2154	the
O	2155	2164	prognosis
O	2165	2167	if
O	2168	2174	deemed
O	2175	2186	appropriate
O	2186	2187	.
